Literature DB >> 32068149

Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center.

Lukasz Kwapisz1, Laura E Raffals2, David H Bruining1, Darrell S Pardi1, William J Tremaine1, Sunanda V Kane1, Konstantinos A Papadakis1, Nayantara Coelho-Prabhu1, John B Kisiel1, Valerie Heron1, William A Faubion1, Edward V Loftus1.   

Abstract

The global incidence of inflammatory bowel disease (IBD) has increased considerably during the past few decades.1 IBDs, composed of Crohn's disease (CD) and ulcerative colitis (UC), are characterized by heterogeneous presentation and widely variable clinical course. The therapeutic goals are to induce and maintain remission. Despite the current treatments available, many patients do not achieve this goal.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Year:  2020        PMID： 32068149     DOI： 10.1016/j.cgh.2020.02.017

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


  11 in total

1.  Double Biologic Therapy for Refractory Stricturing Crohn's Disease: A Successful Case of Deep Remission with Ustekinumab and Vedolizumab.

Authors:  Ahmed Elmoursi; Terrence A Barrett; Courtney Perry
Journal:  Inflamm Bowel Dis       Date:  2020-06-18       Impact factor: 5.325

Review 2.  Selecting the Best Combined Biological Therapy for Refractory Inflammatory Bowel Disease Patients.

Authors:  Eduard Brunet Mas; Xavier Calvet Calvo
Journal:  J Clin Med       Date:  2022-02-18       Impact factor: 4.241

Review 3.  The Essential Role of a Multidisciplinary Approach in Inflammatory Bowel Diseases: Combined Medical-Surgical Treatment in Complex Perianal Fistulas in CD.

Authors:  Jeroen Geldof; Nusrat Iqbal; Janindra Warusavitarne; Ailsa Hart
Journal:  Clin Colon Rectal Surg       Date:  2022-01-17

4.  Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases.

Authors:  Quazim A Alayo; Aava Khatiwada; Anish Patel; Maria Zulfiqar; Anas Gremida; Alexandra Gutierrez; Richard P Rood; Matthew A Ciorba; George Christophi; Parakkal Deepak
Journal:  Inflamm Bowel Dis       Date:  2021-10-18       Impact factor: 7.290

5.  Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease.

Authors:  Quazim A Alayo; Marc Fenster; Osama Altayar; Kerri L Glassner; Ernesto Llano; Kindra Clark-Snustad; Anish Patel; Lukasz Kwapisz; Andres J Yarur; Benjamin L Cohen; Matthew A Ciorba; Deborah Thomas; Scott D Lee; Edward V Loftus; David I Fudman; Bincy P Abraham; Jean-Frederic Colombel; Parakkal Deepak
Journal:  Crohns Colitis 360       Date:  2022-02-10

6.  Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn's disease: A case report and review of literature.

Authors:  Michael Au; Nikola Mitrev; Rupert W Leong; Viraj Kariyawasam
Journal:  World J Clin Cases       Date:  2022-03-16       Impact factor: 1.337

Review 7.  Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature.

Authors:  Magdalena Wlazło; Jarosław Kierkuś
Journal:  J Clin Med       Date:  2022-04-03       Impact factor: 4.241

Review 8.  Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment.

Authors:  Georgios Axiaris; Evanthia Zampeli; Spyridon Michopoulos; Giorgos Bamias
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

Review 9.  Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature.

Authors:  Christine Olbjørn; Jon Bergreen Rove; Jørgen Jahnsen
Journal:  Paediatr Drugs       Date:  2020-08       Impact factor: 3.022

10.  Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study.

Authors:  Laurent Goessens; Jean-Frédéric Colombel; An Outtier; Marc Ferrante; Joao Sabino; Ciaran Judge; Reza Saeidi; Louise Rabbitt; Alessandro Armuzzi; Eugeni Domenech; George Michalopoulos; Anneline Cremer; Francisco Javier García-Alonso; Tamas Molnar; Konstantinos Karmiris; Krisztina Gecse; Joep Van Oostrom; Mark Löwenberg; Klaudia Farkas; Raja Atreya; Davide Giuseppe Ribaldone; Christian Selinger; Frank Hoentjen; Benoit Bihin; Shaji Sebastian; Jean-François Rahier
Journal:  United European Gastroenterol J       Date:  2021-10-25       Impact factor: 4.623
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.